Gemtuzumab Ozogamicin
Acute Myeloid Leukemia With Multilineage Dysplasia
Explore 33 assets in Acute Myeloid Leukemia With Multilineage Dysplasia →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With Multilineage Dysplasia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gemtuzumab Ozogamicin (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Cytarabine | National Cancer Institute (NCI) | P3 | BB |
| Etoposide | Institut de Recherches Internationales Servier | P2 | BB |
| Decitabine | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | BB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Ivosidenib | Institut de Recherches Internationales Servier | P3 | BB |
| Cyclosporin A | Case Comprehensive Cancer Center | P3 | BB |
| Busulfanum | National Cancer Institute (NCI) | P3 | BB |
+41 more in the Acute Myeloid Leukemia With Multilineage Dysplasia cohort
Other indications for Gemtuzumab Ozogamicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Leukemia | — | P3 | BB · 69 |
| Acute Myeloid Leukemia | — | P3 | BB · 67 |
| Myelodysplastic Syndrome | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia With Multilineage Dysplasia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gemtuzumab-ozogamicin-acute-myeloid-leukemia-with-multilineage-dysplasia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →